Market Intelligence, Clinical Progress, and High-Purity Reagents for Allergic Disease and Mast Cell Biology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MS4A2 (FcεRIβ) drug discovery. Because MS4A2 is a complex 4-pass transmembrane protein, we strongly recommend cell-based assays using our validated lentivirus systems to preserve native conformation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Gene Delivery (Lentivirus) | Full-length ORF in lentivirus premade particles. Enables stable cell line construction preserving native tetraspan topology. Sequence Verified. HEK293 background ensures native glycosylation. | View MS4A2 Products |
| Antigen (Full Length) | MS4A2 full-length tetraspanin construct (lentivirus/stable cell line). Native membrane integration, endotoxin controlled. | View MS4A2 Products |
| Antigen (Peptide) | MS4A2 extracellular loop peptides. High purity (>95%), Endotoxin <1EU/μg, Sequence Verified. | View MS4A2 Products |
| Benchmark Antibody | Anti-MS4A2 / Anti-FcεRIβ (research grade). Recombinant positive control for flow cytometry validation and assay development. | View MS4A2 Products |
| Validator (siRNA) | MS4A2 siRNA set. For knockdown verification and specificity controls. | View MS4A2 Products |
| Receptor Complex Partner | FCER1A (FcεRIα) ECD-Fc fusion protein. High purity (>95%), Endotoxin <1EU/μg. For IgE binding competition assays. | View FCER1A Products |
| Signaling Subunit | FCER1G (FcεRIγ) recombinant protein. For functional reconstitution studies and signaling complex analysis. | View FCER1G Products |
| Downstream Kinase | SYK (spleen tyrosine kinase) recombinant protein or assay kit. For downstream degranulation pathway validation. | View SYK Products |
| Selectivity Counter-screen | MS4A1 / CD20 recombinant protein. MS4A family homolog for cross-reactivity testing. HEK293 expressed. | View MS4A1 Products |
| Related Target | IGHG1 / IgE recombinant protein. Ligand for the FcεRI complex; essential for functional assays. | View IGHG1 Products |
| Cross-species Orthologs | Human / Mouse / Cyno MS4A2 stable cell lines and proteins available. Sequence confirmed, high purity (>95%). | View MS4A2 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining native 4-TM membrane conformation | Lentivirus stable cell lines (HEK293) preserve full-length topology, glycosylation, and membrane insertion – bypassing soluble protein misfolding. |
| Cross-species preclinical evaluation (Cyno/Mouse) | Human, mouse, and cynomolgus monkey orthologs available as stable cell lines or purified proteins; theoretical MW documented. |
| MS4A subfamily off-target liability (MS4A1/CD20, MS4A3) | Homolog panel proteins (MS4A1, MS4A3) strictly sequence-verified for counter-screening to avoid unintended B-cell depletion. |
| Functional reconstitution of FcεRI complex | FCER1A ECD-Fc + FCER1G provided; enables heterotrimeric complex assembly validation and calcium flux / degranulation assays. |
| Lack of reliable cellular controls | Clinical benchmark antibody (research grade) and validated siRNA included for expression modulation and specificity checks. |
| False positives in signaling assays | Validated siRNA set allows rigorous biological knockdown confirmation to distinguish on-target vs. off-target effects. |
Live MS4A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MS4A2-directed therapeutics is intensifying, with the allergy and immunology sector shifting focus from systemic anti-IgE biologics to direct modulation of the FcεRI signaling complex. MS4A2, the signal-amplifying tetraspanin beta subunit, represents a differentiated entry point for blocking high-affinity IgE receptor signaling upstream of degranulation. First-generation therapies (e.g., Omalizumab) have validated the pathway, and the next wave of R&D is targeting direct membrane intervention via small molecules, monoclonal antibodies, bispecifics, siRNA/ASO, and degraders. Emerging evidence also links MS4A2 to microglial regulation in neurodegenerative indications (e.g., Alzheimer's disease), opening a CNS-modulator pipeline. Key clinical mutations in MS4A2 (rs569108/E237G, rs35033981, rs535630) are risk factors for atopic dermatitis and asthma, driving companion diagnostic development and precision medicine approaches. Future trends include inhaled siRNA for asthma, combination therapies with anti-IgE to tackle refractory allergies, and targeted protein degradation for mastocytosis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Roche, Early-stage Biotech | Allergic Asthma, Mastocytosis, Chronic Urticaria | Cell-based calcium flux assay using lentivirus-stable MS4A2 lines; need native membrane environment. |
| Monoclonal Antibody (Blocker) | Novartis, Roche, Academic Consortia | Allergic Asthma, Chronic Urticaria | Cell-based binding assay (Flow) using full-length MS4A2 stable cells; need native conformation to avoid agonism. |
| Bispecific Antibodies | Sanofi, Genentech | Severe Food Allergies | Cross-linking validation using native conformation cells; need co-expression of FcεRI complex. |
| siRNA / Nucleic Acid | Alnylam, Ionis, Specialized Immunology Firms | Atopic Dermatitis, Systemic Mastocytosis | Knockdown efficiency validation using MS4A2 siRNA; qPCR/Flow readout controls. |
| Degrader / ADC (Emerging) | Academic / Stealth Biotech | Refractory Allergies, Mastocytosis | Internalization assay using high-purity MS4A2+ cell lines; pH-sensitive dye monitoring. |
| CNS Modulators | Biogen, Academic Consortia | Alzheimer's Disease (Microglia) | Microglial cell line construction; MS4A2 lentivirus transduction for functional studies. |
Key MS4A2 Mutations & Precision Medicine Implications
Clinically relevant mutations in MS4A2 have been documented and impact both disease susceptibility and drug discovery:
- rs569108 (E237G): A well-established risk factor for atopic dermatitis and asthma. This mutation in the transmembrane region may alter receptor signaling efficiency. Assays using mutant MS4A2 (E237G) lentivirus cell lines are critical for developing selective drugs and companion diagnostics.
- rs35033981 (UniProt VAR_053515) and rs535630 (UniProt VAR_053516): Additional missense variants that may influence FcεRI complex stability or IgE binding. Including these variants in selectivity and screening panels helps de-risk development for patient subpopulations.
TarMart offers custom ORF and lentivirus particles for these mutations (e.g., E237G), enabling precise modeling of high-risk genetic backgrounds in functional assays.